{"denoms":[{"counts":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"199"}],"units":"Participants"}],"groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"BG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.5","value":"58.2"},{"groupId":"BG001","spread":"13.9","value":"58.1"},{"groupId":"BG002","spread":"12.9","value":"58.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"72"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"127"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"110"}],"title":"PS 0"},{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"89"}],"title":"PS 1"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"PS 2"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Missing"}]}],"description":"ECOG = Eastern cooperative oncology group PS levels are 0 (Fully active, able to carry on all pre-disease performance), 1 (ambulatory and able to carry out work of a light or sedentary), 2 (Ambulatory and capable of all selfcare but unable to carry out any work activities), 3 (Capable of only limited selfcare, confined to bed or chair more than 50% of awake time), 4 (Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair) and 5 (death).","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status (PS)]","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"113"}],"title":"3rd line"},{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"86"}],"title":"4th line and beyond"}]}],"description":"3rd line: 3rd in sequence of multiple therapies: imatinib (1st); sunitinib (2nd). 4th line and beyond: 4th in sequence of multiple therapies: imatinib (1st); sunitinib (2nd); other (3rd).","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior anti-cancer drug group","unitOfMeasure":"Participants"}]}